ENLV has $16 per share worth of crypto tokens in the balance sheet and SP is at $0.8
Enlivex Ltd. (ENLV) is Nasdaq listed biotech that has a quite promising drug in phase 2. But contrary to the usual biotech firm that is actually not so important thing at this junction. The reason is that there's quite unique opportunity available due to their crypto treasury strategy. They have bought a lot of crypto tokens called RAIN in the past and based on today's market price of the token have accumulated over $16 per share worth of token's in the balance sheet. The share price is currently quite surprisingly at $0.8 which means that they could fairly easily slowly sell some of the tokens and give shareholders dividend that would e.g. equal the current entire share price.
Of course the price of tokens can and will fluctuate a lot based on how the underlying protocol gains or won't gain popularity. But above describes how things are as of today and since the token at least currently has quite large daily trading volume of $50 million it's not one of those small cryptos that nobody has heard of which could explain part of the huge disconnect between the balance sheet and share price.